Jasper Therapeutics (NASDAQ:JSPR) Given “Market Outperform” Rating at JMP Securities

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating restated by JMP Securities in a research report issued on Monday,Benzinga reports. They presently have a $70.00 target price on the stock. JMP Securities’ price target points to a potential upside of 295.26% from the stock’s current price.

Several other analysts also recently commented on JSPR. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $73.38.

Jasper Therapeutics Trading Down 15.1 %

NASDAQ:JSPR opened at $17.71 on Monday. The stock has a market cap of $265.67 million, a price-to-earnings ratio of -3.74 and a beta of 2.18. The stock has a 50-day moving average price of $21.95 and a two-hundred day moving average price of $20.46. Jasper Therapeutics has a 1 year low of $6.61 and a 1 year high of $31.01.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Braidwell LP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $9,091,000. Ally Bridge Group NY LLC grew its stake in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after buying an additional 180,852 shares in the last quarter. Samsara BioCapital LLC increased its holdings in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after buying an additional 59,642 shares during the last quarter. FMR LLC bought a new stake in Jasper Therapeutics during the third quarter worth $722,000. Finally, Bank of New York Mellon Corp acquired a new stake in Jasper Therapeutics in the second quarter valued at $740,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.